Company record · updated August 5, 2026
Latigo Biotherapeutics, Inc.: 4 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs July 17, 2026 to July 17, 2026.
4observations
1source filings
4verified rows
2026-07-17most recent as-of date
Source rails for this company: S-1 charter round (4).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-07-17 | Series SEED price per share | 0.3548 USD | — | VERIFIED | "Original Issue Price" defined for Series SEED | 000119312526307306 |
| 2026-07-17 | Series B price per share | 1.5729 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312526307306 |
| 2026-07-17 | Series A-2 price per share | 0.8987 USD | — | VERIFIED | "Original Issue Price" defined for Series A-2 | 000119312526307306 |
| 2026-07-17 | Series A price per share | 0.6913 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312526307306 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.